Real-life outcomes of subthreshold laser therapy for diabetic macular edema

Table 2 Central macular thickness (CMT) obtained from 23 eyes that underwent baseline and follow up evaluations on the same OCT device, which allowed a quantitative analysis

Eye	Baseline CMT (µm)	Follow up CMT (µm)	CMT change (µm)	Thickness reduction %
1^a	444	354	− 90	20.27
2^a	316	327	11	− 3.48
3^a	370	306	− 64	17.30
4^a	421	263	− 158	37.53
5^a	385	503	118	− 30.65
6^a	264	259	− 5	1.89
7^a	142	161	19	− 13.38
8^a	360	393	33	− 9.17
9^a	480	492	12	− 2.50
10^a	322	287	− 35	10.87
11^a	228	184	− 44	19.30
12^b	532	348	− 184	34.59
13^b	362	315	− 47	12.98
14^b	520	494	− 26	5.00
15^b	508	535	27	− 5.31
16^b	279	258	− 21	7.53
17^b	373	296	− 77	20.64
18^b	285	563	278	− 97.54
19^b	323	256	− 67	20.74
20^b	314	515	201	− 64.01
21^b	392	259	− 133	33.93
22^b	439	430	− 9	2.05
23^b	469	607	138	− 29.42
Mean ± SD	370.8 ± 98.4	365.4 ± 127	− 5.4	1.46

Italic values indicate eyes that had CMT reduction greater than 10% of basal CMT with laser monotherapy. The mean reduction in CMT was not statistically significant (p = 0.815)
^a Baseline and follow up OCT exams performed on the Avanti RTVue device
^b Baseline and follow up OCT exams performed on the Triton Topcon device

ISSN: 2056-9920